ADX-2191 Market Sales
Key Factors Driving ADX-2191 Growth
1. Strong unmet medical need across multiple retinal indications
- Primary vitreoretinal lymphoma (PVRL):
- Rare, aggressive cancer with no approved therapies
- Affects ~300–600 patients/year in the US
- Retinitis pigmentosa (RP):
- Affects >1 million people globally, with most forms lacking approved treatment
- Proliferative vitreoretinopathy (PVR):
- Sight-threatening complication with no approved drug therapy
This broad unmet need across oncology + inherited retinal diseases significantly expands the commercial opportunity.
2. Differentiated, optimized formulation vs compounded methotrexate
- ADX-2191 is a sterile, non-compounded intravitreal formulation specifically designed for ocular use
- Advantages over compounded methotrexate:
- Reduced risk of microbial contamination and vision-threatening complications
- Optimized pH, viscosity, density, and injection volume for retinal delivery
3. Positive clinical efficacy signals (proof-of-concept)
- Phase II trial in RP demonstrated:
- Significant improvements in retinal function and visual acuity
- Statistically significant improvements in:
- Best-corrected visual acuity (P<0.0001)
- Retinal sensitivity and electroretinography responses
- No major safety concerns; drug was well tolerated
Early efficacy and safety data support progression into pivotal Phase II/III studies, a key valuation inflection point.
4. Regulatory advantages accelerating development
- FDA Fast Track Designation (RP) - enables expedited development and review
- Orphan Drug Designation (FDA & EMA) - benefits include:
- Market exclusivity (up to 7–10 years)
- Reduced regulatory costs
5. Established mechanism and clinical precedent
- Methotrexate already widely used off-label intravitreally as standard of care in PVRL
- Cancer cell clearance is linked to injection frequency, with ~5 injections typically required
ADX-2191 Recent Developments
- In August 2025, Aldeyra Therapeutics announced that the US Food and Drug Administration (FDA) had granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa.
“ADX-2191 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ADX-2191 for potential indication like Retinitis pigmentosa and Intraocular lymphoma in the 7MM. A detailed picture of ADX-2191’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ADX-2191 for potential indications. The ADX-2191 market report provides insights about ADX-2191’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ADX-2191 performance, future market assessments inclusive of the ADX-2191 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ADX-2191 sales forecasts, along with factors driving its market.
ADX-2191 Drug Summary
ADX-2191 is a proprietary, intravitreal formulation of methotrexate developed by Aldeyra Therapeutics for the treatment of rare retinal and vitreoretinal diseases. It is being primarily investigated for conditions such as Primary Vitreoretinal Lymphoma and Proliferative Vitreoretinopathy, where uncontrolled cellular proliferation and inflammation can lead to vision loss. ADX-2191 works by inhibiting dihydrofolate reductase, thereby blocking DNA synthesis and cellular replication, which is particularly effective against rapidly dividing malignant or inflammatory cells. Administered via intravitreal injection, the drug is designed to provide targeted, sustained therapeutic concentrations within the eye while minimizing systemic exposure. Clinical studies have demonstrated promising efficacy in controlling disease progression and reducing recurrence rates, along with a manageable safety profile, positioning ADX-2191 as a potential localized treatment option for serious ocular conditions. The report provides ADX-2191’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the ADX-2191 Market Report
The report provides insights into:
- A comprehensive product overview including the ADX-2191 MoA, description, dosage and administration, research and development activities in potential indication like Retinitis pigmentosa and Intraocular lymphoma.
- Elaborated details on ADX-2191 regulatory milestones and other development activities have been provided in ADX-2191 market report.
- The report also highlights ADX-2191‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
- The ADX-2191 market report also covers the patents information, generic entry and impact on cost cut.
- The ADX-2191 market report contains current and forecasted ADX-2191 sales for potential indications till 2034.
- Comprehensive coverage of the late-stage emerging therapies for respective indications.
- The ADX-2191 market report also features the SWOT analysis with analyst views for ADX-2191 in potential indications.
Methodology
The ADX-2191 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ADX-2191 Analytical Perspective by DelveInsight
- In-depth ADX-2191 Market Assessment
This ADX-2191 sales market forecast report provides a detailed market assessment of ADX-2191 for potential indication like Retinitis pigmentosa and Intraocular lymphoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ADX-2191 sales data uptil 2034.
- ADX-2191 Clinical Assessment
The ADX-2191 market report provides the clinical trials information of ADX-2191 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
ADX-2191 Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
ADX-2191 Market Potential & Revenue Forecast
- Projected market size for the ADX-2191 and its key indications
- Estimated ADX-2191 sales potential (ADX-2191 peak sales forecasts)
- ADX-2191 Pricing strategies and reimbursement landscape
ADX-2191 Competitive Intelligence
- Number of competing drugs in development (pipeline analysis)
- ADX-2191 Market positioning compared to existing treatments
- ADX-2191 Strengths & weaknesses relative to competitors
ADX-2191 Regulatory & Commercial Milestones
- ADX-2191 Key regulatory approvals & expected launch timelines
- Commercial partnerships, licensing deals, and M&A activity
ADX-2191 Clinical Differentiation
- ADX-2191 Efficacy & safety advantages over existing drugs
- ADX-2191 Unique selling points
ADX-2191 Market Report Highlights
- In the coming years, the ADX-2191 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
- The ADX-2191 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ADX-2191’s dominance.
- Other emerging products for Retinitis pigmentosa and Intraocular lymphoma are expected to give tough market competition to ADX-2191 and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ADX-2191 in potential indications.
- Analyse ADX-2191 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
- Our in-depth analysis of the forecasted ADX-2191 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ADX-2191 in potential indications.
Key Questions Answered In The ADX-2191 Market Report:
- What is the class of therapy, route of administration and mechanism of action of ADX-2191? How strong is ADX-2191’s clinical and commercial performance?
- What is ADX-2191’s clinical trial status in each individual indications such as Retinitis pigmentosa and Intraocular lymphoma and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ADX-2191 Manufacturers?
- What are the key designations that have been granted to ADX-2191 for potential indications? How are they going to impact ADX-2191’s penetration in various geographies?
- What is the current and forecasted ADX-2191 market scenario for potential indications? What are the key assumptions behind the forecast?
- What are the current and forecasted sales of ADX-2191 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
- What are the other emerging products available and how are these giving competition to ADX-2191 for potential indications?
- Which are the late-stage emerging therapies under development for the treatment of potential indications?
- How cost-effective is ADX-2191? What is the duration of therapy and what are the geographical variations in cost per patient?
